REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. ,.
The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica s microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ .
REHOVOT, Israel, Aug. 15, 2023 /PRNewswire/ Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , has. -Today at 07:01 am- MarketScreener
/PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd..
/PRNewswire/ Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd..